New Brunswick, NJ – FDA OKs New Johnson & Johnson Treatment For Psoriasis

    1

    New Brunswick, NJ – People with the skin disorder psoriasis will have another treatment option after U.S. regulators approved a new drug from Johnson & Johnson.

    Join our WhatsApp group

    Subscribe to our Daily Roundup Email


    The Food and Drug Administration approved Tremfya (trehm-FEYE-eh) Thursday for people with moderate to severe plaque psoriasis.

    Johnson & Johnson said that in one patient study about seven in 10 patients getting Tremfya had clear or nearly clear skin after 24 weeks of treatment, compared with about four in 10 patients receiving rival AbbVie’s Humira, the world’s top selling drug.

    Tremfya, which is injected every eight weeks, can cause infections and other serious side effects. It will cost $9,684 per dose, or about $58,100 per year, without insurance.


    Listen to the VINnews podcast on:

    iTunes | Spotify | Google Podcasts | Stitcher | Podbean | Amazon

    Follow VINnews for Breaking News Updates


    Connect with VINnews

    Join our WhatsApp group


    1 Comment
    Most Voted
    Newest Oldest
    Inline Feedbacks
    View all comments
    6 years ago

    Missing from the article:

    1] “Janssen offers a number of patient support programs, including a co-pay card for patients with commercial insurance that reduces their out-of-pocket cost for TREMFYA™ to no more than $5 per dose.”

    2] I haven’t found the list price in Canada or France or India.